Immunobiology of Ebola and Lassa virus infections (Q30238887)

12 June 2017

Immunobiology of Ebola and Lassa virus infections (English)

1 reference

12 June 2017

Orthoebolavirus zairense

0 references

0 references

3

0 references

Andrea Marzi

object named as

Andrea Marzi

series ordinal

2

0 references

Heinz Feldmann

series ordinal

5

object named as

Heinz Feldmann

1 reference

12 June 2017

6

Sonja M Best

1 reference

12 June 2017

1

Joseph B Prescott

1 reference

12 June 2017

Shelly J Robertson

4

1 reference

12 June 2017

23 January 2017

1 reference

12 June 2017

13

1 reference

Nature Reviews Immunology

inferred from page(s)

published in

1 reference

12 June 2017

17

1 reference

12 June 2017

195-207

1 reference

12 June 2017

3

1 reference

Pathogenesis of the viral hemorrhagic fevers

12 June 2017

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Emergence of Zaire Ebola Virus Disease in Guinea

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Risk maps of Lassa fever in West Africa

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Lassa fever in West Africa: evidence for an expanded region of endemicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Nosocomial outbreak of novel arenavirus infection, southern Africa

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Review of cases of nosocomial Lassa fever in Nigeria: the high price of poor medical practice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Considerations in the Use of Nonhuman Primate Models of Ebola Virus and Marburg Virus Infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Animal models of viral hemorrhagic fever

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Principles of regulatory information conservation between mouse and human

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Ebola virus disease in West Africa--clinical manifestations and management

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Clinical illness and outcomes in patients with Ebola in Sierra Leone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Early clinical sequelae of Ebola virus disease in Sierra Leone: a cross-sectional study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Ebola Virus Disease Complications as Experienced by Survivors in Sierra Leone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Dilemmas in Managing Pregnant Women With Ebola: 2 Case Reports

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Ebola hemorrhagic fever and pregnancy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Lassa fever in Guinea: I. Epidemiology of human disease and clinical observations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

An analysis of features of pathogenesis in two animal models of Ebola virus infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Rodent-Adapted Filoviruses and the Molecular Basis of Pathogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Molecular determinants of Ebola virus virulence in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

A Syrian golden hamster model recapitulating ebola hemorrhagic fever

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Pathogenesis of experimental Ebola Zaire virus infection in BALB/c mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Lassa virus infection of human dendritic cells and macrophages is productive but fails to activate cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Role of interferons in the control of Lassa virus replication in human dendritic cells and macrophages.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Phylogenetic analysis of the Arenaviridae: patterns of virus evolution and evidence for cospeciation between arenaviruses and their rodent hosts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Effective vaccine for lassa fever

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Infection and activation of monocytes by Marburg and Ebola viruses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Interferon-stimulated genes: a complex web of host defenses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Interferon α/β Receptor-Deficient Mice as a Model for Ebola Virus Disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

The role of the Type I interferon response in the resistance of mice to filovirus infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Chimeric Mice with Competent Hematopoietic Immunity Reproduce Key Features of Severe Lassa Fever

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Functional interferon system is required for clearance of lassa virus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Early and strong immune responses are associated with control of viral replication and recovery in lassa virus-infected cynomolgus monkeys

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Broad-spectrum inhibition of retroviral and filoviral particle release by tetherin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Inhibition of Lassa and Marburg virus production by tetherin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Filovirus pathogenesis and immune evasion: insights from Ebola virus and Marburg virus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

RIG-I-like receptor regulation in virus infection and immunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Interferon-inducible effector mechanisms in cell-autonomous immunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Viral tricks to grid-lock the type I interferon system

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

The Ebola virus VP35 protein functions as a type I IFN antagonist.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

A C-terminal basic amino acid motif of Zaire ebolavirus VP35 is essential for type I interferon antagonism and displays high identity with the RNA-binding domain of another interferon antagonist, the NS1 protein of influenza A virus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Structural basis for dsRNA recognition and interferon antagonism by Ebola VP35

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Mutual antagonism between the Ebola virus VP35 protein and the RIG-I activator PACT determines infection outcome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Ebola virus protein VP35 impairs the function of interferon regulatory factor-activating kinases IKKepsilon and TBK-1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Ebola Zaire virus blocks type I interferon production by exploiting the host SUMO modification machinery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Virus infection triggers SUMOylation of IRF3 and IRF7, leading to the negative regulation of type I interferon gene expression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Effects of Filovirus Interferon Antagonists on Responses of Human Monocyte-Derived Dendritic Cells to RNA Virus Infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Ebola virus VP24 proteins inhibit the interaction of NPI-1 subfamily karyopherin alpha proteins with activated STAT1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Ebola virus VP24 targets a unique NLS binding site on karyopherin alpha 5 to selectively compete with nuclear import of phosphorylated STAT1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Inhibition of IRF-3 activation by VP35 is critical for the high level of virulence of ebola virus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Mutations Abrogating VP35 Interaction with Double-Stranded RNA Render Ebola Virus Avirulent in Guinea Pigs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

T cell-derived protein S engages TAM receptor signaling in dendritic cells to control the magnitude of the immune response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Biology of the TAM receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

TIM genes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Virion-associated phosphatidylethanolamine promotes TIM1-mediated infection by Ebola, dengue, and West Nile viruses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Analysis of Ebola Virus Entry Into Macrophages

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Enveloped viruses disable innate immune responses in dendritic cells by direct activation of TAM receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Interaction between Ebola virus glycoprotein and host toll-like receptor 4 leads to induction of proinflammatory cytokines and SOCS1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Suppressor of Cytokine Signaling 3 Is an Inducible Host Factor That Regulates Virus Egress during Ebola Virus Infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

The VP35 protein of Ebola virus inhibits the antiviral effect mediated by double-stranded RNA-dependent protein kinase PKR.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Ebola virus VP35 antagonizes PKR activity through its C-terminal interferon inhibitory domain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Ebola Virus Glycoprotein Promotes Enhanced Viral Egress by Preventing Ebola VP40 From Associating With the Host Restriction Factor BST2/Tetherin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Requirements within the Ebola Viral Glycoprotein for Tetherin Antagonism.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

The Z proteins of pathogenic but not nonpathogenic arenaviruses inhibit RIG-I-like receptor-dependent interferon production

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Structural basis for the dsRNA specificity of the Lassa virus NP exonuclease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Structures of Arenaviral Nucleoproteins with Triphosphate dsRNA Reveal a Unique Mechanism of Immune Suppression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Arenavirus nucleoprotein targets interferon regulatory factor-activating kinase IKKε.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Arenavirus nucleoproteins prevent activation of nuclear factor kappa B.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Identification of cell surface molecules involved in dystroglycan-independent Lassa virus cell entry

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Depletion of peripheral blood T lymphocytes and NK cells during the course of ebola hemorrhagic Fever in cynomolgus macaques

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Human fatal zaire ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Pro- and anti-apoptotic CD95 signaling in T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Human Ebola virus infection results in substantial immune activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Inflammatory responses in Ebola virus-infected patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Interferon-γ: an overview of signals, mechanisms and functions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Markedly elevated levels of interferon (IFN)-gamma, IFN-alpha, interleukin (IL)-2, IL-10, and tumor necrosis factor-alpha associated with fatal Ebola virus infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Cytokine and chemokine expression in humans infected with Sudan Ebola virus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

IL-10: the master regulator of immunity to infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

NRAV, a long noncoding RNA, modulates antiviral responses through suppression of interferon-stimulated gene transcription

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Induced IL-10 splice altering approach to antiviral drug discovery.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Early immune responses accompanying human asymptomatic Ebola infections

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

The balance between IL-1 and IL-1Ra in disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Unique human immune signature of Ebola virus disease in Guinea

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Antibodies to Lassa virus Z protein and nucleoprotein co-occur in human sera from Lassa fever endemic regions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Development of a new vaccine for the prevention of Lassa fever

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Role of lymphocytic choriomeningitis virus (LCMV) in understanding viral immunology: past, present and future

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Old and New World arenaviruses share a highly conserved epitope in the fusion domain of the glycoprotein 2, which is recognized by Lassa virus-specific human CD4+ T-cell clones

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Characterization of human CD4(+) T-cell clones recognizing conserved and variable epitopes of the Lassa virus nucleoprotein

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Human dendritic cells infected with the nonpathogenic Mopeia virus induce stronger T-cell responses than those infected with Lassa virus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Protection of rhesus monkeys from Lassa virus by immunisation with closely related Arenavirus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Clinical care of two patients with Ebola virus disease in the United States

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Human asymptomatic Ebola infection and strong inflammatory response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Clinical virology of Lassa fever in hospitalized patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Regulatory T cell-like responses in deer mice persistently infected with Sin Nombre virus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Innate immune evasion by filoviruses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Reverse genetics systems as tools for the development of novel therapies against filoviruses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Ebola virus disease candidate vaccines under evaluation in clinical trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Ebola virus vaccines - reality or fiction?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

EBOLA VACCINE. VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Advanced vaccine candidates for Lassa fever

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

An attenuated Lassa vaccine in SIV-infected rhesus macaques does not persist or cause arenavirus disease but does elicit Lassa virus-specific immunity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.138

Lassa fever, a new virus disease of man from West Africa. I. Clinical description and pathological findings

31 March 2020

1 reference

12 December 2020

1 reference

12 December 2020

Clinical features of Lassa fever in Liberia

1 reference

12 December 2020

Vesicular stomatitis virus-based vaccines against Lassa and Ebola viruses

1 reference

12 December 2020

Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses

1 reference

12 December 2020

Chimpanzee Adenovirus Vector Ebola Vaccine--Preliminary Report

1 reference

12 December 2020

Comparative pathology of Lassa virus infection in monkeys, guinea-pigs, and Mastomys natalensis

1 reference

12 December 2020

Lassa fever in West African sub-region: an overview

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRI.2016.138

1 reference

12 June 2017

1 reference

PubMed ID

28111475